NCT03160521: A reported trial by Rovi Pharmaceuticals Laboratories
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03160521 |
|---|---|
| Title | Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intramuscular Injections of Risperidone ISM® in Patients With Acute Exacerbation of Schizophrenia |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 2, 2017 |
| Completion date | Dec. 17, 2018 |
| Required reporting date | Dec. 17, 2021, midnight |
| Actual reporting date | Dec. 2, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |